The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 14, 2019

Filed:

Sep. 30, 2013
Applicants:

Foundation for Biomedical Research and Innovation, Hyogo, JP;

Tokai University Educational System, Tokyo, JP;

Stemmed Inc., Hyogo, JP;

Juntendo Educational Foundation, Tokyo, JP;

Inventors:

Takayuki Asahara, Hyogo, JP;

Haruchika Masuda, Kanagawa, JP;

Rika Tanaka, Tokyo, JP;

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 35/44 (2015.01); A61K 35/14 (2015.01); A61K 35/28 (2015.01); A61K 35/15 (2015.01); A61K 35/12 (2015.01); C12N 5/071 (2010.01); C12N 5/0786 (2010.01);
U.S. Cl.
CPC ...
A61K 35/44 (2013.01); A61K 35/14 (2013.01); A61K 35/15 (2013.01); A61K 35/28 (2013.01); C12N 5/0645 (2013.01); C12N 5/0692 (2013.01); A61K 2035/124 (2013.01); C12N 2500/84 (2013.01); C12N 2500/90 (2013.01); C12N 2501/10 (2013.01); C12N 2501/125 (2013.01); C12N 2501/145 (2013.01); C12N 2501/165 (2013.01); C12N 2501/2306 (2013.01); C12N 2501/26 (2013.01); C12N 2502/28 (2013.01);
Abstract

Simplification of a preparation step of a cell population used for the treatment of ischemic diseases, and provision of a cell population that shows more effective treatment are shown. A method of producing a cell population wherein a vascular endothelial progenitor cell and/or an anti-inflammatory macrophage are/is enriched, including cultivating a mononuclear cell derived from bone marrow, cord blood or peripheral blood in a serum-free medium containing stem cell factor, interleukin-6, FMS-like tyrosine kinase 3 ligand, thrombopoietin and vascular endothelial cell growth factor, and proliferating vascular endothelial progenitor cell from the cell; and a cell population obtained by the method are shown.


Find Patent Forward Citations

Loading…